SARS-CoV-2 Envelope Antibody [mFluor Violet 610 SE] Summary
| Immunogen |
This antibody was raised against a peptide corresponding to 14 amino acids near the carboxyl terminus of SARS-CoV-2 (COVID-19) Envelope protein. The immunogen is located within the last 50 amino acids of SARS-CoV-2 (COVID-19) Envelope protein. |
| Predicted Species |
SARS-CoV (93%). Backed by our 100% Guarantee. |
| Isotype |
IgG |
| Clonality |
Polyclonal |
| Host |
Rabbit |
| Gene |
E |
| Purity |
Peptide affinity purified |
| Innovator's Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase. |
Applications/Dilutions
| Dilutions |
- ELISA
- Immunohistochemistry
- Western Blot
|
| Application Notes |
Optimal dilution of this antibody should be experimentally determined. |
Packaging, Storage & Formulations
| Storage |
Store at 4C in the dark. |
| Buffer |
50mM Sodium Borate |
| Preservative |
0.05% Sodium Azide |
| Purity |
Peptide affinity purified |
Notes
mFluor(TM) is a trademark of AAT Bioquest, Inc. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
Alternate Names for SARS-CoV-2 Envelope Antibody [mFluor Violet 610 SE]
Background
The SARS-CoV-2 Envelope protein is one of the four major structural proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19 (1). The envelope protein is the smallest of the four structural proteins, which also includes the membrane protein, spike protein, and nucleocapsid protein (1,2). The envelope protein is synthesized as a 75 amino acid protein with a theoretical molecular weight of approximately 8.4 kDa (2,3). Furthermore, the envelope protein of SARS-CoV-2 has 94.7% sequence identity and 97.4% sequence similarity to the envelope protein of SARS-CoV (2). Structurally, the envelope protein is a membrane protein with a N-terminal domain, an alpha-helical transmembrane domain, and a hydrophilic C-terminal domain (1,4). The envelope protein has multiple functions in viral replication including viral assembly, release, and pathogenesis (2,4). Additionally, the SARS-CoV-2 envelope protein has ion channel activity and functions as a viroporin with a role in virion trafficking (2,4). Coronaviruses lacking the envelope protein are shown to have reduced viral titer and slowed or defective maturation, indicative of a role in virus production and growth (4).
References
1. Malik Y. A. (2020). Properties of Coronavirus and SARS-CoV-2. The Malaysian Journal of Pathology.
2. Yoshimoto F. K. (2020). The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. The Protein Journal. https://doi.org/10.1007/s10930-020-09901-4
3. Uniprot (P0DTC4)
4. J Alsaadi, E. A., & Jones, I. M. (2019). Membrane binding proteins of coronaviruses. Future Virology. https://doi.org/10.2217/fvl-2018-0144
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are
guaranteed for 1 year from date of receipt.
Publications for SARS-CoV-2 Envelope Antibody (NBP3-07060MFV610) (0)
There are no publications for SARS-CoV-2 Envelope Antibody (NBP3-07060MFV610).
By submitting your publication information earn gift cards and discounts for future purchases.
Reviews for SARS-CoV-2 Envelope Antibody (NBP3-07060MFV610) (0)
There are no reviews for SARS-CoV-2 Envelope Antibody (NBP3-07060MFV610).
By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
- Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
- Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
Product General Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
Video Protocols
FAQs for SARS-CoV-2 Envelope Antibody (NBP3-07060MFV610) (0)
Secondary Antibodies
| |
Isotype Controls
|
Additional SARS-CoV-2 Envelope Products
Blogs on SARS-CoV-2 Envelope
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](https://images.novusbio.com/images/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg "Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.")